Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive... Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.
- Mechanism
- Curator reviewed · 1 reference
Arotinolol binds to the β1-, β2- and α1- adrenergic receptor sites with a very high affinity. Radioligand studies have shown that arotinolol presents a higher affinity to the β-receptor compared to the α-receptor. The elucidated mechanism of action seems to be the result of a reduction in the cardiac output via the β-blockade and an additional inhibition of the counter-regulatory increase in peripheral resistance mediated by the α-blockade.
- Primary indication
- Artinolol was introduced to be used as an antihypertensive agent since 1986.Curator reviewed
- Formula / weight
- C15H21N3O2S3 · 371.53 g/mol (avg)
- Code names
- S-596
Resolves to
BHIAIPWSVYSKJS-UHFFFAOYSA-NSMILESCC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=OWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Arotinolol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account